Trial Profile
An Open-label Study to Identify Molecular Markers of Steroid Resistance in Nasal Polyposis Before and Following Treatment With Mometasone Furoate (MFNS) 2 Sprays/Nostril (100 mcg/Nostril) Twice Daily for 4 Weeks
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Mometasone (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MERK2
- 15 May 2018 Status changed from recruiting to discontinued.
- 21 Apr 2015 New trial record